Investigator-initiated Clinical Trial to Observe Conjunctival Goblet Cell Using an Anterior Segment Imaging Device

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · May 19, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a special type of cell in the eye called conjunctival goblet cells, which help keep our eyes moist by producing a substance called mucin. When these cells don’t work properly, it can lead to problems like dry eyes. The researchers have developed a new way to image these cells without surgery, and they want to see how well this method works in people. They will also use 0.5% moxifloxacin eye drops, which are commonly used to treat bacterial eye infections and are safe for use in eye surgeries.

To participate in this trial, you need to be an adult aged 19 or older and either currently using or scheduled to use moxifloxacin eye drops for surgery or to treat certain eye conditions like dry eye or Sjogren's syndrome. Participants will undergo medical examinations and follow-up visits to help monitor their progress. It's important to note that some individuals, such as pregnant or nursing women, or those with certain health conditions, may not be eligible to join the study. This trial is an exciting opportunity to help improve the diagnosis and treatment of eye surface diseases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients aged 19 years or older.
• • Patients who are currently using or scheduled to use 0.5% moxifloxacin eye drops for ophthalmic surgery (control group) or for ocular surface diseases (patient group: dry eye, Sjogren's syndrome, Stevens-Johnson syndrome, graft versus host disease).
• • Patients who have agreed to understand and comply with the clinical trial protocol's plans for medical examinations and follow-up observations.
• Exclusion Criteria:
• • Pregnant or planning to become pregnant, and lactating women.
• • Patients with intellectual disabilities and other psychiatric disorders who, at the discretion of the investigator, are deemed ineligible for participation in the clinical trial.
• • Patients with hypersensitivity reactions to 0.5% moxifloxacin eye drops, or patients for whom administration is contraindicated.
• • Patients for whom participation in the study is deemed impractical based on the judgment of other medical staff and neutral observers (excluding specified selection/exclusion criteria, based on medical reasons, ethical considerations, low compliance, and understanding of the study).